BIOGEN INC.

Listed Company

BIIBCIK 0000875045NasdaqLarge AcceleratedBiological Products, (No Diagnostic Substances)DelawareFY ends Dec 31

Period

FY 2025

Revenue

$9.89B

Net Income

$1.29B

Total Assets

$29.44B

Equity

$18.26B

Shares Out

147.64M

Op. Cash Flow

$2.20B

Business

BIOGEN INC. is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases. It offers marketed therapies for multiple sclerosis, spinal muscular atrophy, Friedreich’s ataxia, ALS, Alzheimer’s disease and psoriasis, as well as biosimilars and investigational assets including antisense oligonucleotides, monoclonal antibodies and small molecules. Its key business segments include neurology, specialized immunology, rare diseases, biosimilars and collaborative commercialization arrangements with partners such as Eisai, Ionis, Genentech and Samsung Bioepis. Biogen commercializes and distributes products primarily through its own sales forces, third‑party partners and specialty and wholesale distributors across the U.S., Europe, Japan and other international markets.

Summary from filing dated 2025-02-12

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenues	9,891	9,676	9,836	10,173	10,982
Cost of sales, excluding amortization and impairment of acquired intangible assets	2,404	2,310	2,533	2,278	2,110
Research and development	1,779	1,980	2,445	2,231	2,501
Acquired in-process research and development, upfront and milestone expense	472	62	17	—	—
Selling, general and administrative	2,434	2,404	2,550	2,404	2,674
Amortization and impairment of acquired intangible assets	515	447	241	366	—
Collaboration profit sharing/(loss reimbursement)	290	254	219	−7	7
(Gain) loss on fair value remeasurement of contingent consideration	34	28	0	−209	−51
Impairment of ROU asset	53	0	0	—	—
Restructuring charges	49	30	219	131	0
Gain on sale of priority review voucher, net	0	−89	0	0	—
Other (income) expense, net	306	344	316	−108	1,096
Total cost and expense	8,334	7,770	8,539	6,582	9,237
Income before income tax (benefit) expense	1,557	1,906	1,297	—	—
Income tax (benefit) expense	264	274	135	633	53
Net income	1,293	1,632	1,162	2,962	1,728
Net income attributable to noncontrolling interests, net of tax	0	0	400,000	−85	172
Net income attributable to Biogen Inc.	1,293	1,632	1,161	3,047	1,556
Basic earnings per share attributable to Biogen Inc. (in dollars per share)	8.83	11.21	8.02	20.96	10.44
Diluted earnings per share attributable to Biogen Inc. (in dollars per share)	8.79	11.18	7.97	20.87	10.4
Weighted-average number of common shares outstanding (in shares)	147	146	145	145	149
Diluted earnings per share attributable to Biogen Inc. (in shares)	147	146	146	146	150

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	3,009	2,375	1,050	3,419	2,261
Current portion of marketable securities	807	0	0	1,474	1,541
Accounts receivable, net of allowance for doubtful accounts of $3.0 and $2.2, respectively	1,342	1,405	1,664	1,705	1,549
Due from anti-CD20 therapeutic programs	525	464	436	431	412
Inventory	2,168	2,461	2,527	1,344	1,352
Other current assets	1,123	753	1,182	1,418	741
Total current assets	8,974	7,457	6,859	9,791	7,857
Marketable securities	432	0	0	706	892
Property, plant and equipment, net	3,055	3,181	3,310	3,299	3,416
Operating lease assets	265	356	420	404	375
Intangible assets, net	9,179	9,691	8,363	1,850	2,221
Goodwill	6,491	6,479	6,219	5,749	5,761
Deferred tax asset	293	324	929	1,226	1,415
Investments and other assets	751	561	745	1,529	1,940
Total assets	29,440	28,049	26,845	24,554	23,877
Current portion of notes payable	0	1,749	150	0	999
Taxes payable	115	548	257	260	175
Accounts payable	432	424	403	492	589
Accrued expense and other	2,803	2,808	2,624	2,521	2,535
Total current liabilities	3,349	5,529	3,434	3,273	4,298
Notes payable	6,287	4,547	6,788	6,281	—
Deferred tax liability	508	191	642	335	695
Long-term operating lease liabilities	290	335	400	333	330
Other long-term liabilities	749	732	781	944	1,321
Total liabilities	11,183	11,333	12,045	11,166	12,918
Commitments, contingencies and guarantees (Notes 22 and 23)	—	—	—	—	—
Preferred stock, par value $0.001 per share	0	0	0	0	—
Common stock, par value $0.0005 per share	100,000	100,000	100,000	100,000	—
Additional paid-in capital	863	569	303	73	68
Accumulated other comprehensive income (loss)	−182	−136	−154	−165	−107
Retained earnings	20,553	19,260	17,628	16,467	13,912
Treasury stock, at cost; 23.8 million and 23.8 million shares, respectively	−2,977	−2,977	−2,977	−2,977	−2,977
Total equity	18,257	16,716	14,799	13,388	10,960
Total liabilities and equity	29,440	28,049	26,845	24,554	23,877

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	780	673	495	518	488
Impairment of intangible assets	8	60	0	120	629
Excess and obsolescence charges related to inventory	29	102	124	336	168
Amortization of acquired inventory step-up	241	230	32	0	0
Acquired in-process research and development	85	0	0	—	—
Share-based compensation	291	291	264	254	239
Deferred income taxes	362	−158	−306	−169	−427
(Gain) loss on strategic investments	19	101	277	266	827
Other	68	160	148	208	202
Accounts receivable	103	222	61	−203	325
Due from anti-CD20 therapeutic programs	−61	−28	−5	−19	1
Inventory	−65	−274	−131	−320	−462
Accrued expense and other current liabilities	171	25	−202	−113	−95
Income tax assets and liabilities	−958	79	−299	−142	231
Other changes in operating assets and liabilities, net	−248	−179	−74	−92	−145
Net cash flow provided by (used in) operating activities	2,205	2,876	1,547	1,384	3,640
Purchases of property, plant and equipment	−154	−154	−277	−240	−258
Proceeds from sales and maturities of marketable securities	23	0	7,381	3,671	3,405
Purchases of marketable securities	−1,258	0	−5,141	−3,449	−3,809
Proceeds from sale of equity interest in Samsung Bioepis	0	407	788	990	0
Proceeds from sale of priority review voucher, net	0	89	0	0	28
Acquired in-process research and development	−50	0	0	0	−18
Acquisitions of intangible assets	−32	−206	−34	−3	−19
Proceeds from sales of strategic investments	57	145	120	0	94
Other	43	−5	−11	24	13
Net cash flow provided by (used in) investing activities	−1,371	−799	−4,101	1,577	−564
Payments related to issuance of stock for share-based compensation arrangements, net	−10	−31	−44	−2	−700,000
Proceeds from borrowings	1,733	0	997	0	0
Repayments of borrowings	−1,750	−650	−810	—	—
Net (distribution) contribution to noncontrolling interest	0	0	12	12	−94
Contingent consideration payments	−280	0	0	—	—
Other	5	−2	−6	−6	−21
Net cash flow provided by (used in) financing activities	−302	−684	149	−1,747	−2,086
Net increase (decrease) in cash and cash equivalents	532	1,393	−2,405	1,214	990
Effect of exchange rate changes on cash and cash equivalents	102	−68	35	−56	−60

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is BIOGEN INC.'s CIK number?

BIOGEN INC.'s SEC CIK number is 0000875045 (875045). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find BIOGEN INC.'s SEC filings?

All of BIOGEN INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did BIOGEN INC. last report earnings?

BIOGEN INC. (BIIB) most recently filed an earnings 8-K with the SEC on Apr 29, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0000875045-26-000042). This is BIOGEN INC.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is BIOGEN INC.'s most recent earnings 8-K?

BIOGEN INC.'s latest earnings 8-K (Item 2.02) was filed Apr 29, 2026 under accession 0000875045-26-000042. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View BIOGEN INC.'s latest earnings 8-K →
Look up any company's CIK number →